Threshold Pharmaceuticals Inc. is a biotechnology company using its expertise in the tumor microenvironment to discover and develop therapeutic agents that selectively target tumor cells for the treatment of patients living with cancer. Threshold's lead investigational small molecule, TH-302, is being evaluated in two pivotal Phase 3 clinical trials and multiple earlier-stage clinical trials. The company has a global license and codevelopment agreement for TH-302 with Merck KGaA, with an option to co-commercialize in the United States.
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Due to permission requirements, not all quotes are shown.
Threshold Pharmaceuticals Inc. Content
Back to Top